Business
Posting of Circular and Timing of General Meeting
Posting of Circular and Timing of General Meeting.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 6836W Evgen Pharma PLC 18 April 2019 \n\nEvgen Pharma plc\n(\"Evgen Pharma\", or the \"Company\")\n \nPosting of Circular \nand\nTiming of General Meeting\nEvgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that further to its announcement of the Placing yesterday (the \"Placing Announcement\"), a shareholder circular, including the notice of General Meeting, and a form of proxy are today being posted to shareholders. The shareholder circular and notice of General Meeting will be made available on the Company's website www.evgen.com\nFurthermore, since the posting of the Placing Announcement yesterday, the timing of the General Meeting has been changed and will now take place on 8 May 2019 at 11.00 a.m. at the offices of finnCap, 60 New Broad Street, London EC2M 1JJ. \nCapitalised terms used in this announcement shall have the same meanings as the definitions in the Placing Announcement.\n \nFor further information please visit www.evgen.com or contact:\n \n\n\n\n\nEvgen Pharma plc \nDr Stephen Franklin, CEO \nRichard Moulson, CFO\nwww.evgen.com\n \n\n\nc/o +44 (0) 20 7466 5000\n\n\n\n\nfinnCap\nGeoff Nash, Teddy Whiley (Corporate Finance)\nAlice Lane, Manasa Patil (ECM)\nwww.finncap.com\n \n\n\n +44 (0) 20 7220 0500 \n\n\n\n\nWG Partners LLP\nNigel Barnes, Claes Spång \n \n\n\n+44 (0) 20 3705 9330\n\n\n\n\nBuchanan\nMark Court, Sophie Wills, Tilly Abraham\[email protected]\n \n\n\n +44 (0) 20 7466 5000\n\n\n\n\n \n \nAbout Evgen Pharma plc\nEvgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. \nThe Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and tr...